LLY vs PFE
LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies. PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas.
Side-by-side fundamentals
| Metric | LLY | PFE | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $1,246.93 | $27.97 | |
| Market cap as of 2026-08-24 | $1.17T | $159.4B | |
| P/E as of 2026-08-24 | 41.85 | 37.03 | PFE lower |
| PEG as of 2026-08-24 | 1.48 | -2.72 | PFE lower |
| Net margin as of 2026-08-24 | +33.5% | +6.8% | LLY higher |
| Gross margin as of 2026-08-24 | +83.4% | +74.7% | LLY higher |
| Operating margin as of 2026-08-24 | +42.2% | +6.8% | LLY higher |
| ROE as of 2026-08-24 | +92.6% | +4.9% | LLY higher |
| ROA as of 2026-08-24 | +22.0% | +2.1% | LLY higher |
| Debt / equity as of 2026-08-24 | 1.62 | 0.74 | PFE lower |
| Revenue growth (YoY) as of 2026-08-24 | +49.6% | -0.2% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | +31.7% | -14.8% | LLY higher |
| Dividend yield as of 2026-08-24 | +0.8% | +5.4% | PFE higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-08-24 | 0.55 | 0.40 | |
| 1-year return as of 2026-08-24 close | +75.2% | +8.1% | LLY higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.